DesCAARTes™ Phase 1 Trial

Clinical trial for patients with mucosal pemphigus vulgaris (mPV)

Recruiting Eligible Patients at U.S. Sites

A Phase 1 Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Mucosal Pemphigus Vulgaris, Sponsored by Cabaletta Bio, Inc.

Learn more about the DesCAARTes™ clinical trial by downloading this brochure

Visit our DesCAARTes™ clinical trial page at ClinicalTrials.gov

Learn About Mucosal Pemphigus Vulgaris

What is mucosal pemphigus vulgaris?

Mucosal pemphigus vulgaris (mPV) is an autoimmune disorder in which painful blisters are formed on the inside of the mouth, nose, throat, eyelids, anus, and genitals. In an autoimmune disorder, your body’s own defense system, the immune system, attacks the body by mistake. In mucosal pemphigus vulgaris, B cells – a type of immune cell in your body – mistakenly attack a protein related to skin cells, called desmoglein 3 (DSG3). B cells are important for fighting infections, but “bad” B cells make antibodies that attack DSG3. This causes formation of painful blisters.

How is mucosal pemphigus vulgaris treated?

Mucosal pemphigus vulgaris can be treated with corticosteroids or immunosuppressant medications. However, these medications suppress the entire immune system. This puts people at risk of serious infections and other side effects. Therefore, new personalized treatment options are needed for people with mucosal pemphigus vulgaris. 

Learn About Our Trial

What is a clinical trial?

A clinical research study is a medical study that helps to answer important questions about an investigational medication or product, such as:

  • How safe is it?
  • What is a safe amount, or dose?
  • Does it work?
  • What dose might work best?

All medications must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications.

What is the DesCAARTes™ Phase 1 Trial?

The DesCAARTes™ study is being done to find the highest dose of an investigational product, autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART), that can safely be given to people with mucosal pemphigus vulgaris. It is sponsored by Cabaletta Bio, Inc. About 30 people with mPV are expected to take part.

What is DSG3-CAART?

The investigational product, DSG3-CAART, will be made from your own T cells. A T cell is a type of white blood cell. White blood cells fight against invaders that enter the body. Your white blood cells, including your T cells, will be collected from your body and your T cells will be changed, or genetically modified, in a laboratory. After the investigational product has been made from your own T cells, it will be returned to you as an infusion through a needle in your vein. The investigational product is designed to change your T cells, so they attack and kill the “bad” B cells in your body that cause pemphigus vulgaris.

Who can participate in the DesCAARTes™ Phase 1 Trial?

You may be able to take part if:

  • You are 18 years of age or older
  • You have been diagnosed with mucosal pemphigus vulgaris
  • You have active disease (at least 1 sore or blister)
  • You have taken at least 1 medication for mucosal pemphigus vulgaris that did not work well enough, had to be stopped because of side effects, and/or was not suitable for you

Learn more about the DesCAARTes™ clinical trial by downloading this brochure

Visit our DesCAARTes™ clinical trial page at ClinicalTrials.gov

Contact Us

Are you wondering if this clinical trial is right for you? A representative from our patient recruitment center would be glad to discuss the study with you. Alternatively, please email the Cabaletta Study Team.

Patient Recruitment Center Contact Information:

Patient Recruitment Center Contact Information:

Phone: +1-800-711-4906

Email*: cabalettatrials@iqvia.com

Cabaletta Study Team::

Email: clinicaltrials@cabalettabio.com

*Please include only your name and telephone number in the email. Someone from the recruitment center will contact you to discuss the study.